Aventis disease

A number of azetidine-based compounds have been disclosed in patent applications from Aventis Pharma for CBi-modulated treatment of diseases such as obesity, Parkinson s disease, schizophrenia, respiratory and neurological diseases [330-334]. Compound (556) was specifically claimed for use in two formulation patent applications [330, 331] for a stable semi-solid composition and oral emulsion composition, respectively. The optional coadministration of an agent that activates norepinephrinergic and se-rotoninergic neurotransmission (for example, sibutramine) or dopaminergic neurotransmission was also claimed for the treatment of obesity. The optional use of a dopamine agonist (for example, levodopa) was claimed... 

Plenty of other researehers were also looking into vac-eines, ineluding Aventis, Wyeth, Glaxo, and a small eompany in Brisbane, California, ealled VaxGen. So were seientists at Harvard, Yale, Emory, the National Institutes of Health, the National Institute of Allergy and Infeetious Diseases, the Institute of Human Virology, and the Aaron Diamond AIDS Research Center in New York. 

Factor 8 + von Willebrand factor Humate-P (Aventis Behring) Von Willebrand s disease... 

The Hexavalent Study Group has compared the immuno-genicity and safety of a new liquid hexavalent vaccine against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b (DTP + IPV + HB + Hib vaccine, manufactured by Aventis Pasteur MSD, Lyon, France) with two reference vaccines, the pentavalent DTP -I- IPV -i- Hib vaccine and the monovalent hepatitis B vaccine, administrated separately at the same visit (9). Infants were randomized to receive either the hexavalent vaccine (n = 423) or (administered at different local sites) the pentavalent and the HB vaccine (n = 425) at 2, 4, and 6 months of age. The hexavalent vaccine was well tolerated (for details, see the monograph Pertussis vaccines). At least one local reaction was reported in 20% of injections with hexavalent vaccine compared with 16% after the receipt of pentavalent vaccine or 3.8% after the receipt of hepatitis B vaccine. These reactions were generally mild and transient. At least one systemic reaction was reported in 46% of injections with hexavalent vaccine, whereas the respective rate for the recipients of pentavalent and HB vaccine was 42%. No vaccine-related serious adverse event occurred during the study. The hexavalent vaccine provided immune responses adequate for protection against the six diseases. 

Aventis Pharma Germany DG Metabolic Diseases Industrial Park Hochst, Bldg. H 825 65926 Frankfurt am Main Germany... 

Clopidogrel is a dmg also known under the trade name Plavix and marketed by Bristol-Myers Squibb (New York, NY) and Sanofi-Aventis (Bridgewater, NJ). Clopidogrel is used in the treatment of coronary artery disease, polpheral vascular disease, and cerebrovascular disease. In 2009, the synthesis of methyl (Zi)-o-chloromandelate (/ )-154) (Scheme 30.29), a key intermediate to (5)-clopidogrel, was described... 

In June 2001, FDA approved Sanofi-Aventis s new antibiotic Ketek to treat pneumonia after finding that it was effective against a virulent antibiotic-resistant bacterium. However, the agency put off approving Ketek for the far less serious diseases of acute bacterial sinusitis (common sinus infections) and... 

---